Home-Based Exercise as Effective as In-Clinic Care for MS
Evidence of equivalence from a controlled trial is useful because 'home-based exercise programs might improve both access and adherence for at least some patients,' said study investigator Deborah Backus, PT, PhD, vice president for research and innovation at the Shepherd Center, Atlanta, Georgia.
The findings were presented May 29 at the Consortium of Multiple Sclerosis Centers (CMSC) 2025 Annual Meeting.
First Phase 3 MS Exercise Trial
Conducted at eight participating US centers, the STEP trial was limited to patients with modest walking impairment. An Expanded Disability Status Scale (EDSS) score of 4.5 to 6.0 was among the entry criteria designed to select a population that was still ambulatory but with a need for intervention to preserve function.
'We wanted patients who can walk with some measured and perceived limitations but who were still able to exercise safely,' said Backus.
The similar facility- and home-based regimens were based on Guidelines for Exercise in MS (GEMS). In one segment of the trial, 189 patients were randomized to the facility-based (GEMS-F) or the home-based (GEMS-H) programs.
In the second segment of the trial, 190 patients were permitted to select their program, creating choice GEMS-F and choice GEMS-H groups that were compared with each other and with the randomized groups.
The primary outcome was the timed 25-foot walk test (T25FW). Other outcomes included the 6-minute walk test (6MWT), change in EDSS, and scores on the 12-item MS walking scale (MSWS-12). All outcomes were evaluated at 16 weeks and again at 52 weeks after the exercise programs were initiated.
Expressed in least-squares means adjusted for age, sex, and baseline EDSS, the improvement from baseline in T25FW was significant for all study groups and was similar between the GEMS-F and GEMS-H groups, in comparisons within and between the randomized and choice patient populations.
Also consistent across all four study groups, a substantial proportion of the improvement was lost between weeks 16 and 52, even if at least a numerical and, in some cases, a statistical advantage was maintained relative to baseline.
The 6MWT and MSWS-12 outcomes showed a similar pattern with a substantial improvement at 16 weeks that eroded over subsequent follow-up. Again, there was a numerical advantage at 52 weeks over baseline in all of the groups even if it did not reach significance in every arm.
The mean group EDSS scores, which were relatively preserved from baseline to week 16 declined from that timepoint to week 52 in all study groups.
There were modest differences in baseline characteristics among the four study groups, but the impact of the COVID pandemic was a major limitation of the study, said Backus. Dropouts by 52 weeks were substantial throughout the study population but were greater among those in the GEMS-H group, who were less likely to return to the facility for assessments.
Although exercise regimens in terms of aerobics and resistant training were the same for all groups, Backus acknowledged that there were some differences in access to equipment.
For example, participants in the GEMS-F group performed aerobic training on treadmills that were not necessarily available to all of those in the GEMS-H group, even if other forms of aerobic exercise were substituted.
Overall, Backus said that exercise intensity and other key aspects, such as coaching, were similar in the GEMS-F and GEMS-H groups.
Evidence Base for At-Home Exercise
Commenting on the findings, Robert W. Motl, PhD, professor of kinesiology, nutrition, and rehabilitation, University of Illinois, Chicago. and a co-chair of the session where the study was presented, noted that regardless of whether patients completed the exercise program at home or in a facility, all of them were provided with resources for fall prevention, and the lack of serious adverse events in any arm is an important finding from this study.
'With no safety differences and a comparable effect, the results provide an evidence basis for exercising at home, which is more convenient for patients and more cost-effective,' Motl said.
Another expert in rehabilitation for patients with MS, Frederick W. Foley, PhD, assistant professor in the Department of Neurology, Albert Einstein School of Medicine, Bronx, New York, agreed that the research provides support for home-based exercise in MS patients.
'There is a need to reduce the dependence of MS patients on care within a hospital or outpatient facility,' said Foley, who was not involved in the trial.
'It is not only less convenient and potentially more costly to receive care in a facility, but patients are also generally more comfortable in their own home,' he said.
The loss of benefit from week 16 to week 52, although expected and consistent with other lifestyle interventions, was disappointing. He pointed out that sustained benefit from exercise is elusive regardless of setting.
'The difficulty of achieving long-term benefit from behavioral interventions is pretty well recognized,' Foley said. He called this the 'biggest challenge' for extending an exercise treatment effect.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Medscape
11 minutes ago
- Medscape
Tocilizumab Delays: A Barrier in Giant Cell Arteritis Care?
TOPLINE: Patients with giant cell arteritis started tocilizumab therapy an average of 43 days after diagnosis, partly because of delays in insurance approval. METHODOLOGY: Overall, 82 patients (average age, 73 years; 60% women; 87% White individuals) newly diagnosed with giant cell arteritis at the University of Washington, Seattle, Washington, between November 2017 and August 2024 were prescribed 162 mg of subcutaneous tocilizumab. Data on demographics, insurance type, and detailed timelines for medication request, approval, and initiation were collected. When available, cost data for tocilizumab were obtained from insurance quotes, along with information on prior authorization requirements, copay assistance, and medication coverage. The time from the initial tocilizumab request to insurance approval and medication start was analyzed, and costs by insurance payer were compared. TAKEAWAY: Delays in approval for and administration of tocilizumab therapy for newly diagnosed giant cell arteritis increase the risk for vision loss, glucocorticoid exposure, and side effects. The average time from tocilizumab request to the start of treatment was 43 days; from request to insurance approval, 17 days; and from approval to medication start, 30 days. Out-of-pocket costs for tocilizumab averaged $1399 for Medicare patients, $823 for those with Medicare Advantage, $211 for those with commercial insurance, and $0 for Medicaid (P < .01). Commercially insured patients used copay cards more often than other payers (P < .01); Medicare or Medicare Advantage patients had a higher utilization of medication coverage from drug manufacturers (P = .04). IN PRACTICE: 'During the study period, there was only one FDA-approved medication for GCA [giant cell arteritis], yet the high cost and delays to medication start remained high. Understanding the delays, costs, and factors that prevent timely therapy is critical to rheumatologic and geriatric care,' the authors of the study wrote. '[T]he results offer important insights into the administrative and financial frustrations related to securing biologic approval and coverage, which has been documented in other conditions,' experts wrote in an editorial. SOURCE: This study was led by Dominique Feterman Jimenez, MD, University of Washington, Seattle. It was published online on March 15, 2025, in The Journal of Rheumatology. LIMITATIONS: The single-center design may limit the generalizability of the findings beyond Washington State because insurance plans vary by state. The predominance of patients with Medicare may also limit applicability of the findings. The small sample size restricted the ability to analyze differences among various Medicare supplemental plans. DISCLOSURES: One author disclosed receiving support from a Rheumatology Research Foundation Investigator Award. The authors declared having no conflicts of interest. This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Medscape
24 minutes ago
- Medscape
US Cuts Injure Canada's Infectious Disease Surveillance
US President Donald Trump's plans to slash discretionary and research funding to the National Institutes of Health and the Centers for Disease Control and Prevention (CDC) by as much as 53% have Canadian public health officials and experts worried. One of the most concerning challenges might be the consequent loss of invaluable surveillance efforts and data, Jasmine Pawa, MD, a public health and preventive medicine specialist physician and adjunct lecturer of clinical public health at the University of Toronto, Toronto, told Medscape Medical News. Pawa is co-author of a recently published editorial on the effects of the US federal government's dismantling of the structures that Canada has long relied on to keep its population healthy and safe. Jasmine Pawa, MD 'We wanted to focus specifically on the health data around numbers and how they relate to communicable diseases,' she said. 'In the short term, we're losing access to a lot of information on US websites that we might have referenced or used, and I'm aware that people might now be using archived or older sources.' In the long term, the ability to track pandemic threats or mitigate the spread of diseases like HIV or avian influenza will likely be impaired. 'If those data don't exist, it means that we cannot measure trends,' she said, which, in turn, affects response planning. Communicable Diseases Increasing While US surveillance and data collection have declined, Canada has been facing an infectious disease crisis. The country has seen substantial increases in the rates of preventable sexually transmitted diseases like syphilis; adult infections rose by as much as 109% and congenital syphilis by as much as 599% between 2018 and 2022. New HIV cases have also been a cause for concern, rising by almost 25% between 2021 and 2022. 'We're also seeing a surge in measles cases in Canada, which you could say is an emerging infectious disease, in the sense that it's previously been controlled,' said Zahid Butt, PhD, Canada research chair in Interdisciplinary Research for Pandemic Preparedness at the University of Waterloo in Waterloo, Ontario. Butt is especially worried about the spread of vaccine-preventable childhood diseases, including pertussis. 'We're seeing more cases because vaccine coverage is not at optimal levels,' he said. Avian flu has also been on the minds of public health officials, said Butt. Though the CDC continues to monitor confirmed human cases, reporting frequency has declined to once monthly, and the responsibility for detection in animals has been transferred to the US Department of Agriculture. 'We've seen an increase in physical cases, mostly in birds, but there's a potential to jump from birds to humans and cause outbreaks,' he said. Pawa and her coauthor wrote that they expected to see rising rates of drug-resistant tuberculosis, which has long been considered a pandemic of the 'poor.' Similar increases (especially local outbreaks) in hepatitis B and imported Oropouche are also anticipated. Widespread Misinformation The surge in health misinformation during the COVID-19 pandemic was largely attributed to social media and conservative news sources such as Fox News . In addition, US government officials during the first Trump administration sought to tamper with data sharing that other countries had long relied on. Fears about health misinformation have returned, according to the coauthors, who pointed to current deliberate efforts by Trump's cabinet to promote misinformation and publicly discredit national health institutions. 'People living in Canada are vulnerable to a cross-border bleed of not only microorganisms, but also of attitudes, health misinformation, and exposure to biased US media,' they wrote. 'In addition to the loss of data, the changes at the US Department of Health and Human Services, especially with regard to Robert F. Kennedy Jr and Make America Healthy Again, green light a lot of dis- and misinformation and falsehoods about health in general,' said Amy Kaler, PhD, professor of sociology at the University of Alberta in Edmonton. Kaler's expertise is the confluence of infectious diseases and social determinants of health. Amy Kaler, PhD 'It doesn't stop at the US-Canada border,' said Kaler, explaining that local media capacity has been dwindling, while platforms like Facebook have banned Canadian news sources. 'The availability of local, reliable, journalistically sound information has declined at the same time exposure to stuff ranging from outright crazy to just plain misinformed coming from the US has increased,' said Kaler. Though research has shown that Canadians trust their healthcare providers, Kaler also pointed out that many Canadians don't have access to primary care (a recent survey showed that more than 1 in 5 adults lacked a primary care physician). 'That gap gets filled by social media nonsense,' she said. Dwindling media sources are only one part of the problem. Kaler teaches in Alberta, which has a far-right government that 'imitates some of the worst of what's happening in the US, in terms of health and infectious diseases.' 'The big problem that I see is their willingness to entertain or give more respect than should be given to the extreme voices that say things like, 'Don't get vaccinated because your DNA will mutate,'' said Kaler. 'While our minister of health has said that people should get vaccinated, it's couched in rhetoric like 'This is a personal and private decision, and every family should weigh the risks and benefits of vaccination,'' explained Kaler. 'It's not vaccine denialism; it's a soft way of encouraging hesitancy.' Strengthening National Capacity Public health experts have long called for a stronger national infrastructure that supports interoperable systems that easily share health data between provinces, territories, and the federal government. Factors that affect equity (eg, socioeconomics or demographics) should also be considered, said Pawa. This type of robust, evolving surveillance system is needed to support domestic public healthcare efforts. 'They're something that we've needed to do anyway, but being focused and pushing it forward now is really important,' she said. At the same time, 'there needs to be a higher accountability for dedicated public health services, a mechanism that requires provinces and territories to pay attention to this, as distinct from other services that they are currently providing,' said Gaynor Watson-Creed, MD, preventive medicine specialist, physician, and associate dean of medicine at Dalhousie University in Halifax. Gaynor Watson-Creed, MD Watson-Creed, a former deputy chief medical officer of health at the Nova Scotia Health Authority, Halifax, recalled that during the first severe acute respiratory syndrome outbreak, public health officials believed that they could create a 'CDC North' that would provide data and surveillance to the world just as CDC had done. 'Now that we're seeing the decline of the collaboration between CDC and its international partners, including Canada, that need is real. And it's not just the need for communicable disease surveillance but a new need for chronic disease surveillance, injury surveillance, and well-being surveillance in this country,' said Watson-Creed. 'We called for federal public health legislation [in 2017] similar to the way that we have federal legislation for acute care services (ie, the Canada Health Act), she added, citing a decline in Canada's public health systems. 'The trouble is that the provincial governments, ministers of health, etc., may not know enough about public health to even know what they don't know.' Clinicians must step up to the plate, said Watson-Creed. 'Clinicians have not stopped long enough to consider what's at the end of the spectrum after primary prevention. Now would be a good time for them to lend their voices to continued efforts to strengthen the primordial prevention end of public health,' which targets the root causes of disease. No funding for the editorial was reported. Pawa, Butt, and Kaler reported having no relevant financial relationships. Watson-Creed provides consultation services through her company, Sweetfire Consulting.
Yahoo
31 minutes ago
- Yahoo
Tapestry to invest $15 million in recycled leather brand Gen Phoenix
(Reuters) -Coach and Kate Spade parent Tapestry will invest $15 million in eco-leather producer Gen Phoenix as part of an effort to make more sustainable leather goods, the companies told Reuters. Tapestry's investment will bring its stake in Gen Phoenix to 9.9%. Tapestry said the partnership will bolster its efforts to attract younger Generation Z consumers - those born from 1997 to 2012 - who have an appetite for sustainable leather goods. The companies' partnership began in 2022 with the launch of Coach's Gen-Z oriented Coachtopia line, which makes products designed with at least 50% recycled leather fibers from waste that are supplied by Gen Phoenix, according to its website. Scott Roe, who is both chief financial and chief operating officer at Tapestry, said Coachtopia is a bellwether for younger consumers' spending habits. 'It's not that Coachtopia is so commercially massive, but it is helping us understand what's important to this really critical demographic,' he said. Roe would not say how much Coachtopia accounts for in Tapestry's total earnings, only that it is 'relatively small.' Gen Phoenix estimates that its materials have an 80% lower carbon footprint than virgin leather. The brands previously collaborated on an uncoated lining material that Coachtopia brought to market in under a year, said Elyse Winer, chief marketing officer at Gen Phoenix. As part of the investment, Gen Phoenix, which sources waste materials from European tanneries and factories, will supply recycled leather to Tapestry for three years. Gen Phoenix CEO John Kennedy said the company is eager to work with all of Tapestry's brands. Roe said it remains to be seen how the recycled material could be used in other product lines. "There's a lot of opportunities to redirect a lot of that waste stream,' he said.
